Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more
Market Cap & Net Worth: Tenaya Therapeutics Inc (TNYA)
Tenaya Therapeutics Inc (NASDAQ:TNYA) has a market capitalization of $185.63 Million ($185.63 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17980 globally and #6757 in its home market, demonstrating a -10.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tenaya Therapeutics Inc's stock price $0.86 by its total outstanding shares 216505885 (216.51 Million).
Tenaya Therapeutics Inc Market Cap History: 2021 to 2026
Tenaya Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $4.10 Billion to $185.63 Million (-46.35% CAGR).
Index Memberships
Tenaya Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #493 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1672 of 3165 |
Weight: Tenaya Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tenaya Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tenaya Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TNYA by Market Capitalization
Companies near Tenaya Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Tenaya Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tenaya Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Tenaya Therapeutics Inc's market cap moved from $4.10 Billion to $ 185.63 Million, with a yearly change of -46.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $185.63 Million | +20.51% |
| 2025 | $154.04 Million | -50.24% |
| 2024 | $309.60 Million | -55.86% |
| 2023 | $701.48 Million | +61.19% |
| 2022 | $435.18 Million | -89.39% |
| 2021 | $4.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tenaya Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $185.63 Million USD |
| MoneyControl | $185.63 Million USD |
| MarketWatch | $185.63 Million USD |
| marketcap.company | $185.63 Million USD |
| Reuters | $185.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.